Form 4: Neogenomics CEO Anthony P. Zook Acquires Shares and Options in Recent Filing
SEC Form 4 Filing
CEO Anthony P. Zook reports acquisition of Neogenomics shares and stock options in a Form 4 filing with the SEC.
Summary
- Anthony P. Zook, CEO of Neogenomics, filed a Form 4 with the SEC.
- The filing reports the acquisition of 18,900 shares of common stock at a price of $7.8793 per share on May 6, 2025.
- Zook also holds derivative securities, including stock options and restricted stock units.
- The stock options have exercise prices of $14.82 and $13.71, with expiration dates in 2033 and 2034, respectively.
- Zook was granted 729,927 premium-price stock options and 421,496 restricted stock units on April 1, 2025, vesting ratably over three years.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing showing the CEO's transactions. The purchase of shares is a mildly positive signal.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
- The vesting of restricted stock units and options aligns the CEO's interests with those of the shareholders over the long term.
Industry Context
Form 4 filings are standard practice for company insiders reporting transactions in their company's securities. This filing provides transparency into the CEO's investment activity in Neogenomics.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 08/10/2024 | Date of exercisable stock option with an expiration date of 08/10/2033. |
| 06/01/2025 | Date of exercisable stock option with an expiration date of 06/01/2034. |
| 04/01/2025 | Mr. Zook was granted 729,927 stock options and 421,496 restricted stock units, vesting ratably over the first three anniversary dates of the grant date. |
| 05/06/2025 | Transaction date for the acquisition of 18,900 shares of common stock. |
| 05/08/2025 | Date of the signature on the Form 4 filing. |
Keywords
Form 4, SEC, Neogenomics, Stock Options, Restricted Stock Units, Anthony P. Zook, CEO, Beneficial Ownership, Acquisition of Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.